Combining Immunotherapy and Targeted Therapy for Kidney Cancer
A combination of an immunotherapy and a molecularly targeted therapy has been approved to treat patients with advanced renal cell carcinoma, kidney cancer.
Progress Against Cancer
A combination of an immunotherapy and a molecularly targeted therapy has been approved to treat patients with advanced renal cell carcinoma, kidney cancer.
A molecularly targeted therapeutic has been approved for use in combination with fulvestrant for treating certain men and women with breast cancer.
A combination of an immunotherapy and a targeted therapeutic recently was approved by the FDA for patients advanced renal cell carcinoma (kidney cancer).
A molecularly targeted therapeutic was approved by the FDA to treating certain patients with urothelial carcinoma, the most common form of bladder cancer.
The FDA expanded the use of the immunotherapeutic atezolizumab in combination with carboplatin and etoposide for certain small-cell lung cancer patients.
The FDA approved the immunotherapeutic atezolizumab to treat certain patients who have locally advanced or metastatic triple-negative breast cancer.
The FDA approved a new molecularly targeted therapeutic for patients ages 2 or older who have been diagnosed with a rare type of blood cancer called blastic plasmacytoid dendritic cell neoplasm.
The FDA recently approved a new anticancer therapeutic for treating patients with childhood acute lymphoblastic leukemia (ALL).
The FDA expanded the use of pembrolizumab to treat certain patients with a rare, aggressive type of skin cancer called Merkel cell carcinoma.
The FDA approved a new molecularly targeted therapeutic called gilteritinib for treating certain patients with acute myeloid leukemia (AML).
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More